LSE:AZNPharmaceuticals
AstraZeneca Trials In IgAN And COPD Support Growth And Valuation Story
AstraZeneca reported positive Phase III trial results for Ultomiris in immunoglobulin A nephropathy (IgAN).
The company also announced strong late stage data for tozorakimab in chronic obstructive pulmonary disease (COPD).
AstraZeneca plans to seek regulatory approvals for both therapies following these outcomes.
The updates highlight progress in expanding its portfolio in rare kidney and chronic respiratory diseases.
AstraZeneca (LSE:AZN), trading at about £145.36, has seen its share price...